Drug
LY3361237
LY3361237 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Withdrawn1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
withdrawn125%
completed250%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
NCT05123586
withdrawnphase_2
Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome
NCT05781451
completedphase_1
A Study of LY3361237 in Participants With Psoriasis
NCT04975295
completedphase_1
A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
NCT03933943
Clinical Trials (4)
Showing 4 of 4 trials
NCT05123586Phase 2
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
NCT05781451Phase 2
Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome
NCT04975295Phase 1
A Study of LY3361237 in Participants With Psoriasis
NCT03933943Phase 1
A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4